Skip to main content
Caplight Logo









Treventis Corporation

Treventis Corporation

Private
TorontoHealthcare & Life Scienceshttps://treventis.com/

Last Round

Grant

Oct 18, 2022

Total Funding Raised

$8.42M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Treventis Corporation is a biotechnology company that develops disease-modifying small molecule drugs for protein misfolding diseases like Alzheimer's.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

small molecule drug discoveryprotein misfolding diseaseneurodegenerative diseasecomputational drug discoveryin-silico drug designtau inhibitorsAlzheimer's diseasecomputer-aided drug designCADDCNS drug discoverydisease-modifying therapydrug licensingpharmaceutical partnershipsALSParkinson's diseaseoral small moleculesoncologyCommon Conformational Morphology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Treventis Corporation Comparables

Compare Treventis Corporation with similar companies based on industry and business-model similarity.

Treventis Corporation comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oligomerix, Inc.
88%
WaveBreak Therapeutics
84%
Aquinnah Pharmaceuticals
84%

Treventis Corporation Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 18, 2022
GrantSep 19, 2013

Key People

Founding team and executive leadership

Donald Weaver

Founder And Chief Medical Officer

Founding Team

Christopher Barden

Founder, CEO

Founding Team

Treventis Corporation Investors

Notable investors and investment history

Treventis Corporation investors
InvestorRounds
U.S. Department of WarGrant
BioAdvance CapitalSeed
Wellcome TrustGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 82% MoM.

  • May 20, 2026

    Monthly visitors grew 84% MoM, from 785 to 1.4K.

Treventis Corporation Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Treventis Corporation Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Treventis Corporation's valuation, stock price, and market status.

Firmographic Details

HeadquartersToronto
Employee Range19
Year Founded2008
Last FundingOct 18, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?